ResMed (RMD) has been drawing attention after recent share performance data showed the stock down over the past week and month, but higher over the past 3 months. That mixed pattern is prompting fresh questions about valuation.
Over the past year, ResMed has seen the share price drift lower, with the year to date share price return down 10.31% and the 1 year total shareholder return declining 19.19%. However, a 12.73% 3 month share price gain hints that selling pressure may be easing as investors reassess the stock around US$219.58 in light of recent results and valuation debates.
Compare ResMed's mixed share performance with other potential opportunities by scanning a hand picked set of 33 high quality undervalued stocks that combine quality fundamentals with compressed valuations.
ResMed is now trading near US$219 after a sharp 3 month rebound and a much weaker year to date. Does that balance of setbacks and recovery still tilt the risk reward toward buyers at this price?
Most Popular Narrative: 11.4% Undervalued
Compared to the narrative fair value of about $247.93, ResMed at $219.58 screens as cheaper, which is why many investors are rechecking the story behind that gap.
Strategic investments in expanding the diagnosis and treatment funnel, including acquisitions like VirtuOx, Ectosense, and Somnoware, are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.
Curious what kind of revenue mix, profit margins, and future earnings multiple that narrative assumes to reach a fair value above $240 for ResMed? The detailed model leans on measured growth, steady profitability, and a valuation level that has to hold up against both sector peers and alternative GLP 1 linked therapies.
Result: Fair Value of $247.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, that story can break if Philips Respironics returns aggressively to the U.S. market, or if tighter reimbursement and cost pressures squeeze ResMed’s pricing power.
Find out about the key risks to this ResMed narrative.
Next Steps
If the ResMed story so far sounds cautiously optimistic, consider moving quickly from reading to checking the underlying numbers yourself and pressure testing the upside case. For a quick snapshot of what the market currently views as positives, review the 4 key rewards
Looking for more ResMed sized investment ideas?
ResMed may be on your radar today, but the next compelling opportunity could be sitting in plain sight if you know where to look and compare.
- Target high quality prospects that pair strong fundamentals with compressed valuations by scanning the 33 high quality undervalued stocks.
- Secure more dependable cash flow candidates by running through the 6 dividend fortresses and focusing on businesses that prioritise shareholder payouts.
- Reduce potential downside in your portfolio by filtering for sturdier balance sheets using the 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com